KRAS and intrahepatic cholangiocarcinoma: No variants in either the TERT promoter or TP53 were identified in the HCCs, and no TP53, CDKN2A/B, KRAS, ARID1A, and IDH1 variations or FGFR2 fusion were present in the ICC.